18 reported cases in records dated 4 Sep – 3 Oct 2026, versus 19 in 5 Aug – 3 Sep 2026 (5.3% lower). A wider record window, 6 Jul – 3 Oct 2026, holds 50 reported cases. Reporting coverage varies; this compares recorded counts and does not establish a fall in incidence. Record dates are source-record dates, not illness-onset dates, and a missing report does not mean zero cases.

374 reported cases in records dated 4 Sep – 3 Oct 2026, versus 520 in 5 Aug – 3 Sep 2026 (28.1% lower). A wider record window, 6 Jul – 3 Oct 2026, holds 1,059 reported cases. Reporting coverage varies; this compares recorded counts and does not establish a fall in incidence. Record dates are source-record dates, not illness-onset dates, and a missing report does not mean zero cases.

2,037 reported cases in records dated 4 Sep – 3 Oct 2026, versus 2,827 in 5 Aug – 3 Sep 2026 (27.9% lower). A wider record window, 6 Jul – 3 Oct 2026, holds 6,945 reported cases. Reporting coverage varies; this compares recorded counts and does not establish a fall in incidence. Record dates are source-record dates, not illness-onset dates, and a missing report does not mean zero cases.

Seasonal influenza in Australia: 25,620 reported cases in the records dated 5 Jul – 2 Oct 2026. Recorded counts from official reports; reporting coverage varies and a missing report does not mean zero cases. No like-for-like earlier window is bound for a comparison. Record dates are source-record dates, not illness-onset dates.

275 reported cases in records dated 3 Sep – 2 Oct 2026, versus 8 in 4 Aug – 2 Sep 2026 (3337.5% higher). A wider record window, 5 Jul – 2 Oct 2026, holds 289 reported cases. Reporting coverage varies; this compares recorded counts and does not establish a rise in incidence. Record dates are source-record dates, not illness-onset dates, and a missing report does not mean zero cases.

1,110 reported cases in records dated 3 Sep – 2 Oct 2026, versus 3,060 in 4 Aug – 2 Sep 2026 (63.7% lower). A wider record window, 5 Jul – 2 Oct 2026, holds 8,366 reported cases. Reporting coverage varies; this compares recorded counts and does not establish a fall in incidence. Record dates are source-record dates, not illness-onset dates, and a missing report does not mean zero cases.

Survodutide reduces weight by 9.8% in adults with obesity and type 2 diabetes. In adults with obesity and type 2 diabetes, survodutide at a weekly dose of 3.6 mg or 6.0 mg resulted in significantly greater weight reduction than placebo. Randomised trial, NEJM, 1 Oct 2026.

Ebola virus disease in Democratic Republic of the Congo: 14,640 reported cases in the records dated 3 Oct 2025 – 2 Oct 2026. Recorded counts from official reports; reporting coverage varies and a missing report does not mean zero cases. No like-for-like earlier window is bound for a comparison. Record dates are source-record dates, not illness-onset dates.

4,130 reported cases in records dated 3 Sep – 2 Oct 2026, versus 3,892 in 4 Aug – 2 Sep 2026 (6.1% higher). A wider record window, 5 Jul – 2 Oct 2026, holds 10,958 reported cases. Reporting coverage varies; this compares recorded counts and does not establish a rise in incidence. Record dates are source-record dates, not illness-onset dates, and a missing report does not mean zero cases.

246 reported cases in records dated 3 Sep – 2 Oct 2026, versus 779 in 4 Aug – 2 Sep 2026 (68.4% lower). A wider record window, 5 Jul – 2 Oct 2026, holds 1,849 reported cases. Reporting coverage varies; this compares recorded counts and does not establish a fall in incidence. Record dates are source-record dates, not illness-onset dates, and a missing report does not mean zero cases.

7,429 reported cases in records dated 3 Sep – 2 Oct 2026, versus 17,748 in 4 Aug – 2 Sep 2026 (58.1% lower). A wider record window, 5 Jul – 2 Oct 2026, holds 48,969 reported cases. Reporting coverage varies; this compares recorded counts and does not establish a fall in incidence. Record dates are source-record dates, not illness-onset dates, and a missing report does not mean zero cases.

Yersiniosis in New Zealand: 79 reported cases in the records dated 5 Jul – 2 Oct 2026. Recorded counts from official reports; reporting coverage varies and a missing report does not mean zero cases. No like-for-like earlier window is bound for a comparison. Record dates are source-record dates, not illness-onset dates.

374 reported cases in records dated 2 Sep – 1 Oct 2026, versus 520 in 3 Aug – 1 Sep 2026 (28.1% lower). A wider record window, 4 Jul – 1 Oct 2026, holds 1,080 reported cases. Reporting coverage varies; this compares recorded counts and does not establish a fall in incidence. Record dates are source-record dates, not illness-onset dates, and a missing report does not mean zero cases.

1,543 reported cases in records dated 2 Sep – 1 Oct 2026, versus 3,085 in 3 Aug – 1 Sep 2026 (50.0% lower). A wider record window, 4 Jul – 1 Oct 2026, holds 4,628 reported cases. Reporting coverage varies; this compares recorded counts and does not establish a fall in incidence. Record dates are source-record dates, not illness-onset dates, and a missing report does not mean zero cases.

CCHF in pregnancy linked to 28.8% maternal death and 57.4% fetal loss in meta-analysis. A meta-analysis of 55 pregnancies found that Crimean-Congo hemorrhagic fever (CCHF) was associated with a 28.8% maternal mortality rate and a 57.4% fetal loss rate. Ribavirin treatment during the third trimester was associated with lower observed maternal mortality rates, with an odds ratio of 0.33 (95% CI 0.13-0.84; p = 0.031). Systematic review, Emerging infectious diseases, 1 Oct 2026.

2,194 reported cases in records dated 2 Sep – 1 Oct 2026, versus 8,483 in 3 Aug – 1 Sep 2026 (74.1% lower). A wider record window, 4 Jul – 1 Oct 2026, holds 15,621 reported cases. Reporting coverage varies; this compares recorded counts and does not establish a fall in incidence. Record dates are source-record dates, not illness-onset dates, and a missing report does not mean zero cases.

Chikungunya fever in France: 207 reported cases in the records dated 2 Oct 2025 – 1 Oct 2026. Recorded counts from official reports; reporting coverage varies and a missing report does not mean zero cases. No like-for-like earlier window is bound for a comparison. Record dates are source-record dates, not illness-onset dates.

246 reported cases in records dated 2 Sep – 1 Oct 2026, versus 948 in 3 Aug – 1 Sep 2026 (74.1% lower). A wider record window, 4 Jul – 1 Oct 2026, holds 1,849 reported cases. Reporting coverage varies; this compares recorded counts and does not establish a fall in incidence. Record dates are source-record dates, not illness-onset dates, and a missing report does not mean zero cases.

7,429 reported cases in records dated 2 Sep – 1 Oct 2026, versus 22,408 in 3 Aug – 1 Sep 2026 (66.8% lower). A wider record window, 4 Jul – 1 Oct 2026, holds 48,969 reported cases. Reporting coverage varies; this compares recorded counts and does not establish a fall in incidence. Record dates are source-record dates, not illness-onset dates, and a missing report does not mean zero cases.

7,061 reported cases in records dated 2 Sep – 1 Oct 2026, versus 4,637 in 3 Aug – 1 Sep 2026 (52.3% higher). A wider record window, 4 Jul – 1 Oct 2026, holds 27,638 reported cases. Reporting coverage varies; this compares recorded counts and does not establish a rise in incidence. Record dates are source-record dates, not illness-onset dates, and a missing report does not mean zero cases.

52 reported cases in records dated 2 Sep – 1 Oct 2026, versus 96 in 3 Aug – 1 Sep 2026 (45.8% lower). A wider record window, 4 Jul – 1 Oct 2026, holds 653 reported cases. Reporting coverage varies; this compares recorded counts and does not establish a fall in incidence. Record dates are source-record dates, not illness-onset dates, and a missing report does not mean zero cases.

Retatrutide 12 mg linked to 18.8% weight loss in adults with obesity and type 2 diabetes. Treatment with retatrutide resulted in substantial improvements in bodyweight and was associated with improvements in glycaemic control in participants with obesity and type 2 diabetes, with a safety profile generally consistent with other molecules with GLP-1 receptor agonism. Randomised trial, Lancet, 29 Sep 2026.

Dengue fever in Italy: 312 reported cases in the records dated 1 Oct 2025 – 30 Sep 2026. Recorded counts from official reports; reporting coverage varies and a missing report does not mean zero cases. No like-for-like earlier window is bound for a comparison. Record dates are source-record dates, not illness-onset dates.

605 cases of cholera have been reported in Rwanda in 2026, with counts running to 31 August 2026. That is already more than the 312 reported in the whole of 2025 (1.9 times as many).

Adneuris Therapeutics, INC. registered NCT07845071 phase 3 trial in pain on 22 Sep 2026, planning 160 participants. Status "recruiting"; primary completion planned 1 Jan 2027; countries: United States. Registry fields copied as recorded. Source: ClinicalTrials.gov.

PCV13 boosts systemic but not mucosal immunity to pneumococcal serotype 3. PCV13 vaccination induced systemic humoral immune responses to both serotypes but they differed in magnitude, duration, and tissue distribution. Early-phase / non-randomised trial · Phase 4, Lancet Microbe, 15 Sep 2026.

EASL guidance recommends resmetirom or semaglutide for non-cirrhotic MASH with fibrosis stages 2-3. A joint EASL-EASD-EASO guideline recommends pharmacotherapy with resmetirom or semaglutide for adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis stages 2-3. The guidance advises using non-invasive tests to identify high-risk patients and individualizing therapy based on cardiometabolic profiles. Guideline, Journal of hepatology, 1 Dec 2026.

45 reported cases in records dated 31 Aug – 29 Sep 2026, versus 153 in 1 Aug – 30 Aug 2026 (70.6% lower). A wider record window, 2 Jul – 29 Sep 2026, holds 399 reported cases. Reporting coverage varies; this compares recorded counts and does not establish a fall in incidence. Record dates are source-record dates, not illness-onset dates, and a missing report does not mean zero cases.

51 reported cases in records dated 31 Aug – 29 Sep 2026, versus 141 in 1 Aug – 30 Aug 2026 (63.8% lower). A wider record window, 2 Jul – 29 Sep 2026, holds 281 reported cases. Reporting coverage varies; this compares recorded counts and does not establish a fall in incidence. Record dates are source-record dates, not illness-onset dates, and a missing report does not mean zero cases.

52 reported cases in records dated 31 Aug – 29 Sep 2026, versus 120 in 1 Aug – 30 Aug 2026 (56.7% lower). A wider record window, 2 Jul – 29 Sep 2026, holds 653 reported cases. Reporting coverage varies; this compares recorded counts and does not establish a fall in incidence. Record dates are source-record dates, not illness-onset dates, and a missing report does not mean zero cases.

204 reported cases in records dated 31 Aug – 29 Sep 2026, versus 201 in 1 Aug – 30 Aug 2026 (1.5% higher). A wider record window, 2 Jul – 29 Sep 2026, holds 524 reported cases. Reporting coverage varies; this compares recorded counts and does not establish a rise in incidence. Record dates are source-record dates, not illness-onset dates, and a missing report does not mean zero cases.

798 reported cases in records dated 31 Aug – 29 Sep 2026, versus 721 in 1 Aug – 30 Aug 2026 (10.7% higher). A wider record window, 2 Jul – 29 Sep 2026, holds 2,061 reported cases. Reporting coverage varies; this compares recorded counts and does not establish a rise in incidence. Record dates are source-record dates, not illness-onset dates, and a missing report does not mean zero cases.

Rozanolixizumab fails to show broad efficacy in severe fibromyalgia trial. Rozanolixizumab did not demonstrate broad efficacy in this severe fibromyalgia population. Randomised trial, Lancet Rheumatology, 16 Sep 2026.

Escitalopram and amitriptyline linked to higher QTc intervals in depression trials, but no rise in early heart events. The effect of specific antidepressants on QTc interval differed between adults with depression. Systematic review, BMJ, 23 Sep 2026.

Faecal microbiota transplantation does not improve irritable bowel syndrome symptoms in phase 3 trial. The trial did not show a clinical benefit of faecal microbiota transplantation in patients with IBS. Randomised trial, Lancet, 24 Sep 2026.

Adjuvant radiotherapy after surgery reduces recurrence in atypical meningioma. Our findings suggest that adjuvant radiotherapy should be considered in patients with atypical meningioma after complete surgical resection of atypical meningioma when the prevention of recurrence is valued higher than the potential delayed adverse effects of radiotherapy. Randomised trial, Lancet, 25 Sep 2026.

30-day benznidazole regimen matches standard efficacy with fewer side effects in Chagas disease trial. Benznidazole 150 mg once daily for 30 days showed non-inferior efficacy and the lowest rate of drug-related adverse events among the regimens tested, supporting its adoption as the preferred benznidazole regimen for chronic Chagas disease; phase 3 trials of long-term efficacy across parasite genotypes and settings are required to support its incorporation into treatment guidelines. Randomised trial, Lancet Infectious diseases, 22 Sep 2026.

467 reported cases in records dated 31 Aug – 29 Sep 2026, versus 727 in 1 Aug – 30 Aug 2026 (35.8% lower). A wider record window, 2 Jul – 29 Sep 2026, holds 1,849 reported cases. Reporting coverage varies; this compares recorded counts and does not establish a fall in incidence. Record dates are source-record dates, not illness-onset dates, and a missing report does not mean zero cases.

Dengue fever in India: 13,331 reported cases in the records dated 30 Sep 2025 – 29 Sep 2026. Recorded counts from official reports; reporting coverage varies and a missing report does not mean zero cases. No like-for-like earlier window is bound for a comparison. Record dates are source-record dates, not illness-onset dates.

7,742 reported cases in records dated 31 Aug – 29 Sep 2026, versus 10,856 in 1 Aug – 30 Aug 2026 (28.7% lower). A wider record window, 2 Jul – 29 Sep 2026, holds 23,968 reported cases. Reporting coverage varies; this compares recorded counts and does not establish a fall in incidence. Record dates are source-record dates, not illness-onset dates, and a missing report does not mean zero cases.

638 cases of hepatitis A have been reported in Taiwan in 2026, with counts running to 24 September 2026. That is already more than the 480 reported in the whole of 2025 (1.3 times as many).

796 cases of measles have been reported in France in 2026, with counts running to 20 September 2026. That is already more than the 112 reported in the whole of 2025 (7.1 times as many).

881 cases of cholera have been reported in Congo in 2026, with counts running to 13 July 2026. That is already more than the 826 reported in the whole of 2025 (1.1 times as many).

1,512 cases of hepatitis A have been reported in South Korea in 2026, with counts running to 21 September 2026. That is already more than the 1,132 reported in the whole of 2025 (1.3 times as many).

3,150 cases of cholera have been reported in Malawi in 2026, with counts running to 29 June 2026. That is already more than the 214 reported in the whole of 2025 (14.7 times as many).

7,990 cases of cholera have been reported in Mozambique in 2026, with counts running to 17 August 2026. That is already more than the 5,934 reported in the whole of 2025 (1.3 times as many).

65,690 cases of cholera have been reported in Nigeria in 2026, with counts running to 17 August 2026. That is already more than the 23,885 reported in the whole of 2025 (2.8 times as many).